The FACS analysis showed that CD8+ T cells constituted 4.1% of the total lymphocytes in the GPC3-expressing tumor and 1.51% in the tumor formed by injection of the control HM-1 cells (Fig. 4A and B). The gene discussed is CD8A; the disease is neoplasm.